Organogenesis Holdings (ORGO) Net Income towards Common Stockholders (2016 - 2026)

Organogenesis Holdings' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 160.1% year-over-year to -$56.2 million; the TTM figure through Mar 2026 stood at -$13.1 million (up 36.0% YoY), while the FY2025 annual figure was $25.7 million, up 2838.74% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$56.2 million, down from $40.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $40.8 million in Q4 2025, with the low at -$56.2 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $1.4 million (2023), against an average of -$771294.1.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders jumped 1373.02% in 2023, then sank 928.14% in 2025.
• Organogenesis Holdings' Net Income towards Common Stockholders stood at $7.5 million in 2022, then slumped by 80.71% to $1.4 million in 2023, then jumped by 306.86% to $5.9 million in 2024, then jumped by 593.82% to $40.8 million in 2025, then sank by 237.77% to -$56.2 million in 2026.
• Business Quant data shows ORGO's Net Income towards Common Stockholders at -$56.2 million in Q1 2026, $40.8 million in Q4 2025, and $14.5 million in Q3 2025.